{
  "_comment": "Mock RCT/RWE corpus for Obesity ResponderSubpheno tool. NOT real abstracts. Used for structural demonstration only.",
  "studies": [
    {"id": "STEP-1", "year": 2021, "drug_class": "glp1_ra", "subphenotypes": ["default_essential"], "time_weeks": 68, "n": 1961, "weight_loss_pct": -14.9, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "STEP-2", "year": 2021, "drug_class": "glp1_ra", "subphenotypes": ["default_essential"], "time_weeks": 68, "n": 1210, "weight_loss_pct": -9.6, "type": "RCT_published", "km_digitized": true, "korean_site": false, "note": "T2D 동반"},
    {"id": "STEP-3", "year": 2021, "drug_class": "glp1_ra", "subphenotypes": ["default_essential"], "time_weeks": 68, "n": 611, "weight_loss_pct": -16.0, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "STEP-4", "year": 2021, "drug_class": "glp1_ra", "subphenotypes": ["default_essential"], "time_weeks": 68, "n": 803, "weight_loss_pct": -7.9, "type": "RCT_published", "km_digitized": true, "korean_site": false, "maintenance_mode": "post_discontinuation"},
    {"id": "STEP-5", "year": 2022, "drug_class": "glp1_ra", "subphenotypes": ["default_essential"], "time_weeks": 104, "n": 304, "weight_loss_pct": -15.2, "type": "RCT_published", "km_digitized": true, "korean_site": false, "maintenance_mode": "persistence"},
    {"id": "STEP-6", "year": 2022, "drug_class": "glp1_ra", "subphenotypes": ["default_essential", "adipose_visceral"], "time_weeks": 68, "n": 401, "weight_loss_pct": -13.2, "type": "RCT_published", "km_digitized": true, "korean_site": true, "note": "East Asian cohort"},
    {"id": "STEP-TEENS", "year": 2022, "drug_class": "glp1_ra", "subphenotypes": ["adolescent_obesity"], "time_weeks": 68, "n": 201, "weight_loss_pct": -16.1, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "STEP-HFpEF", "year": 2023, "drug_class": "glp1_ra", "subphenotypes": ["default_essential"], "time_weeks": 52, "n": 529, "weight_loss_pct": -13.3, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "SURMOUNT-1", "year": 2022, "drug_class": "glp1_gip_dual", "subphenotypes": ["default_essential"], "time_weeks": 72, "n": 2539, "weight_loss_pct": -20.9, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "SURMOUNT-2", "year": 2023, "drug_class": "glp1_gip_dual", "subphenotypes": ["default_essential"], "time_weeks": 72, "n": 938, "weight_loss_pct": -15.7, "type": "RCT_published", "km_digitized": true, "korean_site": false, "note": "T2D"},
    {"id": "SURMOUNT-3", "year": 2024, "drug_class": "glp1_gip_dual", "subphenotypes": ["default_essential"], "time_weeks": 72, "n": 579, "weight_loss_pct": -18.4, "type": "RCT_published", "km_digitized": true, "korean_site": false, "note": "intensive lifestyle lead-in"},
    {"id": "SURMOUNT-4", "year": 2024, "drug_class": "glp1_gip_dual", "subphenotypes": ["default_essential"], "time_weeks": 88, "n": 670, "weight_loss_pct": -14.0, "type": "RCT_published", "km_digitized": true, "korean_site": false, "maintenance_mode": "post_discontinuation"},
    {"id": "SURMOUNT-OSA", "year": 2024, "drug_class": "glp1_gip_dual", "subphenotypes": ["default_essential"], "time_weeks": 52, "n": 469, "weight_loss_pct": -18.1, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "SURPASS-2", "year": 2021, "drug_class": "glp1_gip_dual", "subphenotypes": ["default_essential"], "time_weeks": 40, "n": 1879, "weight_loss_pct": -12.4, "type": "RCT_published", "km_digitized": true, "korean_site": true, "note": "T2D primary, weight secondary"},
    {"id": "SELECT", "year": 2023, "drug_class": "glp1_ra", "subphenotypes": ["default_essential"], "time_weeks": 208, "n": 17604, "weight_loss_pct": -9.4, "type": "RCT_published", "km_digitized": true, "korean_site": false, "outcome": "MACE"},
    {"id": "OASIS-1", "year": 2023, "drug_class": "oral_glp1", "subphenotypes": ["default_essential"], "time_weeks": 68, "n": 667, "weight_loss_pct": -15.1, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "OASIS-4", "year": 2025, "drug_class": "oral_glp1", "subphenotypes": ["default_essential"], "time_weeks": 64, "n": 307, "weight_loss_pct": -13.6, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "PIONEER-PLUS", "year": 2024, "drug_class": "oral_glp1", "subphenotypes": ["default_essential"], "time_weeks": 52, "n": 1606, "weight_loss_pct": -7.0, "type": "RCT_published", "km_digitized": true, "korean_site": true, "note": "T2D"},
    {"id": "REDEFINE-1", "year": 2025, "drug_class": "cagrisema", "subphenotypes": ["default_essential"], "time_weeks": 68, "n": 3417, "weight_loss_pct": -22.7, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "REDEFINE-2", "year": 2025, "drug_class": "cagrisema", "subphenotypes": ["default_essential"], "time_weeks": 68, "n": 1206, "weight_loss_pct": -15.7, "type": "RCT_published", "km_digitized": true, "korean_site": false, "note": "T2D"},
    {"id": "TRIUMPH-1", "year": 2025, "drug_class": "triple_agonist", "subphenotypes": ["default_essential"], "time_weeks": 48, "n": 338, "weight_loss_pct": -24.2, "type": "RCT_published", "km_digitized": true, "korean_site": false, "note": "retatrutide"},
    {"id": "SYNERGY-NASH", "year": 2024, "drug_class": "triple_agonist", "subphenotypes": ["hepatic_predominant_mash"], "time_weeks": 48, "n": 295, "weight_loss_pct": -10.4, "type": "RCT_published", "km_digitized": true, "korean_site": false, "note": "survodutide MASH"},
    {"id": "MARITIDE-2A", "year": 2025, "drug_class": "maritide", "subphenotypes": ["default_essential"], "time_weeks": 52, "n": 592, "weight_loss_pct": -20.0, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "ATTAIN-1", "year": 2025, "drug_class": "oral_glp1", "subphenotypes": ["default_essential"], "time_weeks": 72, "n": 3127, "weight_loss_pct": -12.4, "type": "RCT_published", "km_digitized": true, "korean_site": true, "note": "orforglipron"},
    {"id": "BBS-IMCIVREE", "year": 2020, "drug_class": "setmelanotide", "subphenotypes": ["bbs_syndromic"], "time_weeks": 52, "n": 44, "weight_loss_pct": -11.6, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "POMC-LEPR-PHASE3", "year": 2020, "drug_class": "setmelanotide", "subphenotypes": ["monogenic_lepr_mc4r_pomc"], "time_weeks": 52, "n": 21, "weight_loss_pct": -25.4, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "SAXENDA-SCALE-1", "year": 2015, "drug_class": "saxenda", "subphenotypes": ["default_essential"], "time_weeks": 56, "n": 3731, "weight_loss_pct": -8.0, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "SAXENDA-PEDS", "year": 2020, "drug_class": "saxenda", "subphenotypes": ["adolescent_obesity"], "time_weeks": 56, "n": 251, "weight_loss_pct": -4.6, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "ORLISTAT-XENICAL-LT", "year": 2004, "drug_class": "orlistat", "subphenotypes": ["default_essential"], "time_weeks": 104, "n": 3304, "weight_loss_pct": -5.4, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "EMPA-REG-WEIGHT", "year": 2018, "drug_class": "sglt2i", "subphenotypes": ["default_essential"], "time_weeks": 52, "n": 7020, "weight_loss_pct": -2.5, "type": "RCT_published", "km_digitized": true, "korean_site": false, "note": "T2D 2차분석"},
    {"id": "DAPA-MASH-KR", "year": 2024, "drug_class": "sglt2i", "subphenotypes": ["hepatic_predominant_mash"], "time_weeks": 24, "n": 86, "weight_loss_pct": -3.3, "type": "RCT_published", "km_digitized": true, "korean_site": true, "note": "small KR study"},
    {"id": "MET-PCOS-KR", "year": 2019, "drug_class": "metformin", "subphenotypes": ["pcos_hyperandrogenic"], "time_weeks": 24, "n": 110, "weight_loss_pct": -3.1, "type": "RCT_published", "km_digitized": true, "korean_site": true},
    {"id": "KORACO-RWE-2024", "year": 2024, "drug_class": "glp1_ra", "subphenotypes": ["default_essential", "adipose_visceral"], "time_weeks": 52, "n": 1240, "weight_loss_pct": -8.7, "type": "RWE_registry", "km_digitized": false, "korean_site": true},
    {"id": "BBSTOPCOACH-RWE", "year": 2025, "drug_class": "glp1_ra", "subphenotypes": ["default_essential"], "time_weeks": 24, "n": 480, "weight_loss_pct": -7.2, "type": "RWE_registry", "km_digitized": false, "korean_site": true, "note": "BBStopCoach RWE"},
    {"id": "NHIS-OBESITY-RX-2023", "year": 2023, "drug_class": "saxenda", "subphenotypes": ["default_essential"], "time_weeks": 52, "n": 18421, "weight_loss_pct": -4.2, "type": "RWE_registry", "km_digitized": false, "korean_site": true, "note": "claims-based weight estimation"},
    {"id": "KOGES-ADOLESCENT", "year": 2022, "drug_class": "metformin", "subphenotypes": ["adolescent_obesity"], "time_weeks": 52, "n": 320, "weight_loss_pct": -1.8, "type": "RWE_registry", "km_digitized": false, "korean_site": true},
    {"id": "K-CURE-BARI-REGAIN", "year": 2024, "drug_class": "glp1_ra", "subphenotypes": ["post_bariatric_regain"], "time_weeks": 52, "n": 95, "weight_loss_pct": -9.1, "type": "RWE_registry", "km_digitized": false, "korean_site": true},
    {"id": "CRANIO-OBESITY-EU", "year": 2023, "drug_class": "glp1_ra", "subphenotypes": ["hypothalamic_obesity"], "time_weeks": 52, "n": 28, "weight_loss_pct": -5.8, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "HYPOTHAL-SETMELANO", "year": 2024, "drug_class": "setmelanotide", "subphenotypes": ["hypothalamic_obesity"], "time_weeks": 52, "n": 18, "weight_loss_pct": -7.6, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "PCOS-SEMA-PILOT", "year": 2024, "drug_class": "glp1_ra", "subphenotypes": ["pcos_hyperandrogenic"], "time_weeks": 24, "n": 60, "weight_loss_pct": -7.5, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "SARC-OBESITY-KOR", "year": 2024, "drug_class": "glp1_ra", "subphenotypes": ["sarcopenic_obesity"], "time_weeks": 24, "n": 88, "weight_loss_pct": -6.9, "type": "RCT_published", "km_digitized": true, "korean_site": true},
    {"id": "MASH-TIRZ-1", "year": 2024, "drug_class": "glp1_gip_dual", "subphenotypes": ["hepatic_predominant_mash"], "time_weeks": 52, "n": 190, "weight_loss_pct": -19.3, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "POSTBARI-TIRZ", "year": 2025, "drug_class": "glp1_gip_dual", "subphenotypes": ["post_bariatric_regain"], "time_weeks": 52, "n": 41, "weight_loss_pct": -14.1, "type": "RCT_published", "km_digitized": true, "korean_site": false},
    {"id": "ORLISTAT-CAH-RETRO", "year": 2018, "drug_class": "orlistat", "subphenotypes": ["cah_obesity"], "time_weeks": 52, "n": 32, "weight_loss_pct": -4.0, "type": "RWE_registry", "km_digitized": false, "korean_site": false},
    {"id": "SURMOUNT-MMO", "year": 2025, "drug_class": "glp1_gip_dual", "subphenotypes": ["default_essential"], "time_weeks": 176, "n": 15375, "weight_loss_pct": -16.7, "type": "RCT_ongoing", "km_digitized": false, "korean_site": false, "note": "CV outcomes"},
    {"id": "EMPOWER-KR-LEAN-MASH", "year": 2025, "drug_class": "glp1_gip_dual", "subphenotypes": ["hepatic_predominant_mash"], "time_weeks": 52, "n": 220, "weight_loss_pct": -11.8, "type": "RCT_ongoing", "km_digitized": false, "korean_site": true},
    {"id": "VISCERAL-CT-KR-PILOT", "year": 2023, "drug_class": "glp1_ra", "subphenotypes": ["adipose_visceral"], "time_weeks": 24, "n": 50, "weight_loss_pct": -6.4, "type": "RCT_published", "km_digitized": true, "korean_site": true},
    {"id": "KOR-ADOL-SEMA-IIT", "year": 2025, "drug_class": "glp1_ra", "subphenotypes": ["adolescent_obesity"], "time_weeks": 52, "n": 70, "weight_loss_pct": -10.2, "type": "RCT_ongoing", "km_digitized": false, "korean_site": true}
  ]
}